about
Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsinIntra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophreniaLimitations of conventional inhibitor classificationsA versatile equation to describe reversible enzyme inhibition and activation kinetics: modeling beta-galactosidase and butyrylcholinesteraseEnzyme-linked DNA dendrimer nanosensors for acetylcholineRetention of function in the DNA homolog of the RNA dopamine aptamer.Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram.Analysis of bacterial, fungal and archaeal populations from a municipal wastewater treatment plant developing an innovative aerobic granular sludge process.In situ biosensing with a surface plasmon resonance fiber grating aptasensor.Are improper kinetic models hampering drug development?Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants.Differential effects of lipid-lowering agents on human cholinesterases.Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives.Potentially procholinergic effects of medications commonly used in older adults.Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase.Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.Homocysteine thiolactone and human cholinesterasesResponse to the Article "Enzyme-Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality"
P50
Q24291720-47AA8482-A296-4584-B29F-68302FDAD710Q27332082-4B2AFB3A-4C13-4D9A-A6AC-CACCFC20744CQ28251848-25E9FF87-04B9-41FA-8B4F-16E2065FB8DCQ28288768-DAA250B2-DFA6-4589-83BA-9329EE53D953Q30667098-2D3963FF-E11F-4958-B278-C3AA47C851C8Q34998857-E2FECE6B-BE6E-47A2-9C7E-F53C9442FBF8Q35687175-E1C1C1A2-AD2B-46C7-BBAD-26C669540BB5Q36203822-94940968-CF06-455B-9F8B-7E0058B8CE7BQ38332899-DE12BC78-F0FC-4A32-B70F-883713E72C4CQ42971858-EEF2BD36-3301-48AE-A2EE-D9173B2E0B33Q43151112-B39A0358-F2B7-4A96-98C5-29C405E50922Q44693378-E72399CB-EAC0-4C72-85C3-798042A5269BQ45176094-6C630F28-EF14-425B-A599-6095F3C5EA93Q46319095-4D01E284-1FBE-4E58-A380-7B3DF144214AQ46526599-8C573EAB-1D23-453B-9ADA-BE37F9CFD919Q53388044-7183A5A8-510B-4BE6-B31E-0EC7B04D8501Q80218560-FE1F9AE1-882A-48B1-9EF1-F92B2C70C46DQ90076185-FAA34B30-B938-4CE9-9756-925E8A4A9100
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ryan Walsh
@ast
Ryan Walsh
@en
Ryan Walsh
@es
Ryan Walsh
@nl
type
label
Ryan Walsh
@ast
Ryan Walsh
@en
Ryan Walsh
@es
Ryan Walsh
@nl
prefLabel
Ryan Walsh
@ast
Ryan Walsh
@en
Ryan Walsh
@es
Ryan Walsh
@nl
P106
P1153
7201781998
P31
P496
0000-0002-3794-4721